Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:30 a.m. ET and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:40 p.m. ET. Both events will be webcast live, accessible via Relay Therapeutics' website, and archived for 30 days post-event. The company focuses on precision medicines, integrating advanced computational and experimental technologies to enhance drug discovery in oncology and genetic disease.
- None.
- None.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 5:40 p.m. ET.
Both the Cowen 3rd Annual Oncology Innovation Summit and the Goldman Sachs 43rd Annual Global Healthcare Conference will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following each event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of disparate technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When is Relay Therapeutics participating in the Cowen 3rd Annual Oncology Innovation Summit?
What are the dates of Relay Therapeutics' fireside chats in June 2022?
How can I watch the Relay Therapeutics fireside chats?
Will Relay Therapeutics' fireside chats be available after the events?
What is the focus of Relay Therapeutics?
